NASDAQ:BLSM BlossomHill Therapeutics (BLSM) Stock Price, News & Analysis $14.59 -0.54 (-3.57%) As of 04:00 PM Eastern Add Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsFDA EventsInsider TradesNews and TrendsSEC FilingsShort Interest About BlossomHill Therapeutics Stock (NASDAQ:BLSM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BLSM alerts:Sign Up Key Stats Today's Range$14.34▼$16.7550-Day Range$12.35▼$26.8252-Week Range$11.02▼$27.99Volume280,172 shsAverage Volume205,672 shsMarket Capitalization$463.67 millionP/E RatioN/ADividend YieldN/APrice Target$35.00Consensus RatingModerate Buy Company Overview BlossomHill Therapeutics is a biotechnology company focused on developing medicines for cancer. Its research has centered on targeted small-molecule treatments designed to address cancer-related genetic changes. The company’s pipeline has included BH-306, an investigational inhibitor of mutant IDH1 being developed for cancers associated with that mutation. The program is in development and is not a marketed treatment. Publicly available information about the company’s leadership and geographic operations is limited.AI Generated. May Contain Errors. Read More BlossomHill Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreBLSM MarketRank™: 3.144850498335 of 5 starsBlossomHill Therapeutics scored higher than 63% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingBlossomHill Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialBlossomHill Therapeutics has a consensus price target of $35.00, representing about 138.1% upside from its current price of $14.70.Amount of Analyst CoverageBlossomHill Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BlossomHill Therapeutics' stock forecast and price target. Earnings and Valuation0.7 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BlossomHill Therapeutics are expected to grow in the coming year, from ($5.54) to ($3.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BlossomHill Therapeutics is -1.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBlossomHill Therapeutics has a P/B Ratio of 2.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted1.86% of the float of BlossomHill Therapeutics has been sold short.Short Interest Ratio / Days to CoverBlossomHill Therapeutics has a short interest ratio ("days to cover") of 4.65.Change versus previous monthShort interest in BlossomHill Therapeutics has recently increased by 21.69%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBlossomHill Therapeutics does not currently pay a dividend.Dividend GrowthBlossomHill Therapeutics does not have a long track record of dividend growth. News and Social Media1.8 / 5News Sentiment-0.20 News SentimentBlossomHill Therapeutics has a news sentiment score of -0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of companies.News Coverage This WeekMarketBeat has tracked 7 news articles for BlossomHill Therapeutics this week, compared to 5 articles on an average week.Search Interest2 people have searched for BLSM on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added BlossomHill Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BlossomHill Therapeutics insiders have not sold or bought any company stock.Percentage Held by InstitutionsBlossomHill Therapeutics has minimal institutional ownership at this time.Read more about BlossomHill Therapeutics' insider trading history. Receive BLSM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BlossomHill Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BLSM Stock News HeadlinesBlossomHill Therapeutics (NASDAQ:BLSM) Stock Gets Downgrade from Wall Street ZenNovember 14, 2026 | americanbankingnews.comBlossomHill Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 13, 2026 | marketscreener.comMWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 18 at 1:00 AM | Base Camp Trading (Ad)BlossomHill Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 13, 2026 | marketscreener.comMBlossomHill Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business HighlightsNovember 13, 2026 | markets.businessinsider.comBlossomHill Therapeutics to Advance BH-30643 to Phase 2 After FDA Alignment on DosageNovember 9, 2026 | marketscreener.comMBlossomHill To Start Pivotal SOLARA-2 Trial Of BH-30643 In Q1 2027; Stock UpNovember 9, 2026 | rttnews.comBlossomHill Therapeutics Announces Outcome from the End-of-Phase 1 Meeting with the FDA and Pivotal Phase 2 Trial Design for OMNI-EGFR™ Inhibitor, BH-30643, in EGFR C797S ...November 9, 2026 | finance.yahoo.comSee More Headlines BLSM Stock Analysis - Frequently Asked Questions How have BLSM shares performed this year? BlossomHill Therapeutics' stock was trading at $16.00 on August 7, 2026. Since then, BLSM shares have decreased by 8.1% and is now trading at $14.70. How were BlossomHill Therapeutics' earnings last quarter? BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) announced its quarterly earnings data on Thursday, November, 12th. The company reported ($1.29) earnings per share for the quarter, missing the consensus estimate of ($0.93) by $0.36. When did BlossomHill Therapeutics IPO? BlossomHill Therapeutics (BLSM) raised $150 million in an initial public offering on Friday, August 7th 2026. The company issued 9,375,000 shares at a price of $16.00 per share. How do I buy shares of BlossomHill Therapeutics? Shares of BLSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/12/2026Today11/18/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:BLSM CIK1839970 Webbhtherapeutics.com Phone858-732-3880FaxN/AEmployees69Year FoundedN/APrice Target and Rating Average Price Target for BlossomHill Therapeutics$35.00 High Price Target$40.00 Low Price Target$28.00 Potential Upside/Downside+139.9%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($8.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$60.56 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-52.53% Debt Debt-to-Equity RatioN/A Current Ratio12.82 Quick Ratio12.82 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.64 per share Price / Book2.20Miscellaneous Outstanding Shares31,780,000Free FloatN/AMarket Cap$463.67 million OptionableN/A BetaN/A 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:BLSM) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BlossomHill Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BlossomHill Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.